These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 36689720)
1. [Androgens and Parkinson's disease: the role in humans and in experiment]. Hamadyanova AU; Kuznetsov KO; Gaifullina EI; Kalandin DA; Khamidullina RR; Khalitova IF; Faizov RM; Kamaletdinova NO; Aslanova BF; Nakieva AG; Burangulova LE; Gaisina GO Probl Endokrinol (Mosk); 2022 Sep; 68(6):146-156. PubMed ID: 36689720 [TBL] [Abstract][Full Text] [Related]
2. Androgens and Parkinson's Disease: A Review of Human Studies and Animal Models. Bourque M; Soulet D; Di Paolo T Androg Clin Res Ther; 2021; 2(1):294-303. PubMed ID: 35024696 [TBL] [Abstract][Full Text] [Related]
3. Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice. Litim N; Morissette M; Caruso D; Melcangi RC; Di Paolo T J Steroid Biochem Mol Biol; 2017 Nov; 174():242-256. PubMed ID: 28982631 [TBL] [Abstract][Full Text] [Related]
4. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130 [TBL] [Abstract][Full Text] [Related]
5. Dutasteride combined with androgen receptor antagonists inhibit glioblastoma U87 cell metabolism, proliferation, and invasion capacity: Androgen regulation. Orozco M; Valdez RA; Ramos L; Cabeza M; Segovia J; Romano MC Steroids; 2020 Dec; 164():108733. PubMed ID: 32980365 [TBL] [Abstract][Full Text] [Related]
6. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease. Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269 [TBL] [Abstract][Full Text] [Related]
7. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease. Bourque M; Morissette M; Di Paolo T Neuropharmacology; 2019 Mar; 147():37-54. PubMed ID: 29649433 [TBL] [Abstract][Full Text] [Related]
8. Limited influence of dutasteride on individual prostate-specific antigen variability in men with clinical benign prostatic hyperplasia. Takeshita H; Kawakami S; Kagawa M; Yano A; Okada Y; Morozumi M Int J Urol; 2018 Jun; 25(6):633-634. PubMed ID: 29693288 [No Abstract] [Full Text] [Related]
10. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Traish AM; Krakowsky Y; Doros G; Morgentaler A Sex Med Rev; 2019 Jan; 7(1):95-114. PubMed ID: 30098986 [TBL] [Abstract][Full Text] [Related]
11. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics. Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730 [TBL] [Abstract][Full Text] [Related]
12. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967 [TBL] [Abstract][Full Text] [Related]
13. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. Tindall DJ; Rittmaster RS J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514 [TBL] [Abstract][Full Text] [Related]
14. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. Traish AM Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108 [TBL] [Abstract][Full Text] [Related]
15. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study. Matsukawa Y; Kato M; Funahashi Y; Majima T; Yamamoto T; Gotoh M Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554 [TBL] [Abstract][Full Text] [Related]
16. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors. Mäkelä VJ; Kotsar A; Tammela TLJ; Murtola TJ J Urol; 2018 Oct; 200(4):743-748. PubMed ID: 29730200 [TBL] [Abstract][Full Text] [Related]
17. Restorative effects of red onion (Allium cepa L.) juice on erectile function after-treatment with 5α-reductase inhibitor in rats. Yilmaz-Oral D; Onder A; Kaya-Sezginer E; Oztekin CV; Zor M; Gur S Int J Impot Res; 2022 Apr; 34(3):269-276. PubMed ID: 33820978 [TBL] [Abstract][Full Text] [Related]
18. Role of 5α-reductase inhibitors in androgen-stimulated skin disorders. Azzouni F; Zeitouni N; Mohler J J Drugs Dermatol; 2013 Feb; 12(2):e30-5. PubMed ID: 23377402 [TBL] [Abstract][Full Text] [Related]
19. [The role of steroid hormones in the neurodegenerative diseases]. Sadowska A; Grzesiak M Postepy Biochem; 2022 Dec; 68(4):387-398. PubMed ID: 36649137 [TBL] [Abstract][Full Text] [Related]
20. Androgenetic alopecia; drug safety and therapeutic strategies. Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]